NO981374L - Dendrittcellestimulerende faktor - Google Patents

Dendrittcellestimulerende faktor

Info

Publication number
NO981374L
NO981374L NO981374A NO981374A NO981374L NO 981374 L NO981374 L NO 981374L NO 981374 A NO981374 A NO 981374A NO 981374 A NO981374 A NO 981374A NO 981374 L NO981374 L NO 981374L
Authority
NO
Norway
Prior art keywords
cells
stimulating factor
dendritic cell
cell stimulating
vivo
Prior art date
Application number
NO981374A
Other languages
English (en)
Norwegian (no)
Other versions
NO981374D0 (no
Inventor
Kenneth Brasel
Stewart D Lyman
Eugene Maraskovsky
Hilary R Mckenna
David H Lynch
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO981374D0 publication Critical patent/NO981374D0/no
Publication of NO981374L publication Critical patent/NO981374L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
NO981374A 1995-10-04 1998-03-26 Dendrittcellestimulerende faktor NO981374L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53914295A 1995-10-04 1995-10-04
PCT/US1996/015990 WO1997012633A1 (en) 1995-10-04 1996-10-03 Dendritic cell stimulatory factor

Publications (2)

Publication Number Publication Date
NO981374D0 NO981374D0 (no) 1998-03-26
NO981374L true NO981374L (no) 1998-06-03

Family

ID=24149974

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981374A NO981374L (no) 1995-10-04 1998-03-26 Dendrittcellestimulerende faktor

Country Status (23)

Country Link
EP (1) EP0871487B1 (de)
JP (1) JP3631496B2 (de)
KR (2) KR100676792B1 (de)
CN (1) CN1172718C (de)
AT (1) ATE432085T1 (de)
AU (1) AU697539B2 (de)
BR (1) BR9610802A (de)
CA (1) CA2232865A1 (de)
CZ (1) CZ97798A3 (de)
DE (1) DE69637942D1 (de)
EA (1) EA199800272A1 (de)
EE (1) EE9800105A (de)
ES (1) ES2323818T3 (de)
IS (1) IS4703A (de)
LV (1) LV12085B (de)
NO (1) NO981374L (de)
NZ (1) NZ321039A (de)
PL (1) PL187329B1 (de)
RO (1) RO120579B1 (de)
SI (1) SI9620116A (de)
SK (1) SK40898A3 (de)
TR (1) TR199800607T1 (de)
WO (1) WO1997012633A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US9068164B1 (en) * 1995-02-02 2015-06-30 Tristem Trading (Cyprus) Limited Method of preparing an undifferentiated cell
KR20000022445A (ko) * 1996-07-10 2000-04-25 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 수상돌기 세포의 활성화 방법
AUPO388396A0 (en) * 1996-11-27 1996-12-19 Ludwig Institute For Cancer Research Cellular adjuvant
AU7835898A (en) * 1997-06-17 1999-01-04 Immunex Corporation A method of enhancing antigen-specific peripheral immune tolerance
FR2775692B1 (fr) * 1998-03-03 2000-06-16 Roussy Inst Gustave Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre
US6849452B1 (en) 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods
FR2782524B1 (fr) * 1998-08-21 2002-07-19 Roussy Inst Gustave Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre
DK1733735T3 (en) 1998-05-22 2017-06-19 Ottawa Hospital Res Inst Methods and products for the induction of mucosal immunity
WO1999062537A1 (en) * 1998-06-04 1999-12-09 The Rockefeller University Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins
US6291661B1 (en) 1998-07-02 2001-09-18 Immunex Corporation flt3-L mutants and method of use
US6838086B1 (en) 1998-08-27 2005-01-04 Universitaetsklinikum Freiburg Composition comprising low molecular weight hyaluronic acid fragments
GB9827604D0 (en) * 1998-12-15 1999-02-10 Lorantis Ltd Methods of immunosuppression
WO2001009303A2 (en) * 1999-07-30 2001-02-08 Vical Inc. Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER
EP1240343A2 (de) * 1999-11-03 2002-09-18 Powderject Vaccines, Inc. Dns impfstoffzusammensetzungen basierend auf cd80/cd86 genpromoter-kontrollierter expression des antigens
AU2001239873A1 (en) * 2000-02-24 2001-09-03 The Board Of Trustees Of The Leland Stanford Junior University Adjuvant treatment by in vivo activation of dendritic cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
EP1276501B9 (de) * 2000-04-25 2007-01-24 Immunex Corporation Behandlung von tumoren mit photodynamischer therapie
US20040247563A1 (en) * 2000-11-02 2004-12-09 Lynch David H. Method of enhancing lymphocyte-mediated immune responses
WO2002040044A2 (en) * 2000-11-17 2002-05-23 Immunex Corporation Chemoattractant recruitment of dendritic cells for enhancement of immunization
EP2322603B1 (de) * 2001-09-06 2019-10-16 NorthWest Biotherapeutics, Inc. Zusammensetzungen und Verfahren für die Aktivierung von monocytischen Dendritischen Zellen und T-Zellen auf Th1-Antwort
KR100490308B1 (ko) * 2002-02-25 2005-05-17 크레아젠 주식회사 면역 치료용 성숙화된 수지상 세포 백신의 제조방법
JP2005528373A (ja) * 2002-03-26 2005-09-22 イミュネックス・コーポレーション 免疫プロトコルにＦｌｔ３リガンドを用いる方法
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
KR100522526B1 (ko) * 2002-11-28 2005-10-19 주식회사 바이넥스 면역 치료용 수지상 세포의 제조방법
KR100614220B1 (ko) * 2004-11-08 2006-08-21 고려대학교 산학협력단 Ｆｌｔ3 리간드 유전자를 발현하는 살모넬라 균주 및 이를함유하는 항암 치료용 조성물
DE102005016234B4 (de) * 2005-04-08 2008-05-15 Tgc Biomics Gmbh Verfahren zur Einschleusung von exogenem Antigen in den MHC I-Präsentationsweg von Zellen
KR100818215B1 (ko) 2006-10-11 2008-04-01 재단법인서울대학교산학협력재단 Ｃｄ３４양성 줄기세포로부터 ｔ 임파구 전구체를 제조하는 방법
KR101264811B1 (ko) 2011-05-20 2013-05-15 충남대학교산학협력단 마이코박테리움 압세수스의 ＭＡＢ０９８１ｃ 단백질을 이용한 수지상 세포의 성숙방법
CN109563481B (zh) * 2016-07-13 2024-01-05 俄亥俄州创新基金会 用于优化宿主抗原呈递和宿主抗肿瘤和抗病原体免疫的平台和方法
CN113544152B (zh) 2018-12-18 2024-10-15 勃林格殷格翰国际加拿大公司 Flt3激动剂抗体及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US826250A (en) 1905-12-20 1906-07-17 Albert Huck Switch for toy railways.
US4714680B1 (en) 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
EP0790307A1 (de) 1986-12-16 1997-08-20 Gist-Brocades B.V. Molekulare Klonierung und Expression von menschlichem IL-3
OA09736A (en) 1987-02-18 1993-11-30 Schering Biotech Corp "Human interleukin-3 and muteins thereof".
EP0391892A4 (en) 1987-10-30 1990-11-28 Immunex Corporation Nonglycosylated analogs of human colony stimulating factors
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5108910A (en) 1989-08-22 1992-04-28 Immunex Corporation DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
DK0423980T3 (da) 1989-10-16 2000-10-09 Amgen Inc Stamcellefaktor
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
ATE220715T1 (de) 1991-10-23 2002-08-15 Nexell Therapeutics Inc Verfahren zur selektiven vermehrung von cd34 positiven zellen
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
NZ314644A (en) 1993-05-24 2000-11-24 Immunex Corp Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue
US5405772A (en) * 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells

Also Published As

Publication number Publication date
EA199800272A1 (ru) 1998-10-29
KR100514957B1 (ko) 2005-11-25
NZ321039A (en) 2001-03-30
LV12085A (lv) 1998-07-20
ATE432085T1 (de) 2009-06-15
SI9620116A (sl) 1999-08-31
KR20040079421A (ko) 2004-09-14
SK40898A3 (en) 1999-04-13
IS4703A (is) 1998-03-26
CN1229359A (zh) 1999-09-22
CN1172718C (zh) 2004-10-27
NO981374D0 (no) 1998-03-26
WO1997012633A1 (en) 1997-04-10
KR100676792B1 (ko) 2007-02-02
AU697539B2 (en) 1998-10-08
CA2232865A1 (en) 1997-04-10
ES2323818T3 (es) 2009-07-24
JP3631496B2 (ja) 2005-03-23
RO120579B1 (ro) 2006-04-28
JPH11513389A (ja) 1999-11-16
EP0871487B1 (de) 2009-05-27
EP0871487A1 (de) 1998-10-21
AU7392296A (en) 1997-04-28
TR199800607T1 (xx) 1998-06-22
BR9610802A (pt) 1999-07-13
PL325964A1 (en) 1998-08-17
EE9800105A (et) 1998-10-15
EP0871487A4 (de) 2004-09-01
PL187329B1 (pl) 2004-06-30
CZ97798A3 (cs) 1999-02-17
DE69637942D1 (de) 2009-07-09
LV12085B (en) 1998-09-20
KR19990063818A (ko) 1999-07-26

Similar Documents

Publication Publication Date Title
EE9800105A (et) Dendriitrakke stimuleeriv faktor
GR3036951T3 (en) Cells with multiple altered epitopes on a surface antigen for use in transplantation
Baldwin et al. Immunology of spontaneously arising rat mammary adenocarcinomas
DE69533964D1 (de) Orale immunisierung durch verwendung von transgenen pflanzen
ATE195875T1 (de) Spezifische modulationen des immunsystems
EP1690934A3 (de) Bildung von xenogenen Antikörpern
Riggins et al. Immunity to spontaneous and methylcholanthrene-induced tumors in inbred mice
EP0871414A4 (de) Behandeltes gewebe zur implantation, sowie herstellungsverfahren
NZ333607A (en) Method of stimulating the immune system by transfecting dendritic cells
NZ322910A (en) Tumour vaccine containing tumour cells, some with MHC-I-haplotype on cell surface to trigger immune response, and preparation of vaccine thereof
DE2967036D1 (en) Vaccine and method of making
Kedar et al. In vitro induction of cell-mediated immunity to murine leukemia cells. I. Optimization of tissue culture conditions for the generation of cytotoxic lymphocytes
Somani et al. Reimmunization after allogeneic bone marrow transplantation
DK1021196T3 (da) Anvendelse af en kemisk stabiliseret chloritoplösning til inhibering af en antigenspecifik immunreaktion
DE60040672D1 (de) Antikörper-abhängige vergrösserung der alphavirus-infektvität
AR015237A1 (es) Una composicion de membranas celulares tumorales modificadas con hapteno, metodo para obtenerlas y su uso.
Ullrich IMMUNOLOGIC FUNCTION OF ALVEOLAR MACROPHAGES: INTERACTION WITH A SOLUBLE PROTEIN ANTIGEN AND THE IMMUNOGENICITY OF ALVEOLAR MACROPHAGE-BOUND ANTIGEN.
DE60130634D1 (de) Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
AU1256495A (en) Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor
SE8205247L (sv) Fiskvacciner
Yefenof et al. Nonimmunogenic radiation-induced lymphoma: Immunity induction by a somatic cell hybrid
MX2026001604A (es) Proteinas modificadas
Neri et al. Influence of neuraminidase and mitomycin C on the immunogenicity of Novikoff tumor cells
Castro An overview of tumour immunology and immunotherapy
RUSSELL Transplantation of tissues and organs